Parkinsons Disease Therapeutics Market, By Drug Class (Levodopa, Dopamine agonists, MAO-B inhibitors, Anticholinergics, Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine, among Others)), By Route of Administration (Oral, Injectable, Nasal, Transdermal, Others (Rectal, Sublingual, among Others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)
Parkinsons disease is a movement disorder caused by a neurological condition. Tremor, slowness of movement, tight muscles, an unsteady walk, balance, and coordination issues are all common symptoms of Parkinson disease. Levodopa, dopamine agonists, MAO-B inhibitors, and anticholinergics are some of the medications used for the treatment of Parkinson’s disease. Levodopa (also called L-dopa) is the most commonly prescribed drug for Parkinson’s disease. It is useful in controlling symptoms such as slow movements and stiff and rigid body parts. Medication allows the majority of patients to retain a high quality of life, and surgery can help some people improve their symptoms. Parkinson's disease patients also observe a decrease in another neurotransmitter known as norepinephrine. This molecule is required for the sympathetic nervous system to operate properly. Some of the body's autonomic activities are controlled by this system, including digestion, heart rate, blood pressure, and breathing. Some of the non-movement-related symptoms of Parkinson's disease are caused by a lack of norepinephrine. Exercise can considerably improve Parkinson's symptoms. Physical therapy, occupational therapy, and speech-language therapy can also assist with walking and balance issues, eating and swallowing difficulties, and speech disorders.
Market Dynamics
Market players are focusing on new product launches, which is expected to propel the Parkinsons disease therapeutic market growth during the forecast period. For instance, in May 2020, Sunovion Pharmaceuticals Inc., a pharmaceutical company, announced that it received U.S. Food and Drug Administration (FDA) approval for KYNMOBI (apomorphine hydrochloride) sublingual film for the acute, intermittent treatment for OFF episodes (i.e., re-emergence or worsening of PD symptoms) in patients with Parkinson’s disease. KYNMOBI is available in different strengths, such as 10mg, 15mg, 20mg, and 25mg.
Key features of the study:
- This report provides an in-depth analysis of the global Parkinsons Disease Therapeutic Market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global Parkinsons disease therapeutic market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., Boehringer Ingelheim International GmbH, Denali Therapeutics Inc., Biogen Inc., Prevail Therapeutics, Eli Lilly and Company and Voyager Therapeutics
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global Parkinsons disease therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Parkinsons disease therapeutic market.
- By Drug Class:
- Levodopa
- Dopamine agonists
- MAO-B inhibitors
- Anticholinergics
- Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine, among Others)
- By Route of Admnistration:
- Oral
- Injectable
- Nasal
- Transdermal
- Others (Rectal, Sublingual, among Others)
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
- Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- GlaxoSmithKline Plc.
- AbbVie Inc.
- Merck & Co., Inc.
- Zydus Cadila
- Dr. Reddy’s Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Boehringer Ingelheim International GmbH
- Denali Therapeutics Inc.
- Biogen Inc.
- Prevail Therapeutics
- Eli Lilly and Company
- Voyager Therapeutics.
- 1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- 4. Global Parkinsons Disease Therapeutics Market – COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
- 5. Global Parkinsons Disease Therapeutics Market, By Drug Class, 2018– 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018–2030
- Segment Trends
- Levodopa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
- Segment Trends
- Dopamine agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Segment Trends
- MAO-B inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Segment Trends
- Anticholinergics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Segment Trends
- Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine, among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Segment Trends
- 6. Global Parkinsons Disease Therapeutics Market, By Route of Administration, 2018–2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018–2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Segment Trends
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Segment Trends
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Segment Trends
- Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Segment Trends
- Others (Rectal, Sublingual, among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Segment Trends
- 7. Global Parkinsons Disease Therapeutics Market, By Distribution Channel, 2018–2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018–2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- 8. Global Parkinsons Disease Therapeutics Market, By Region, 2018–2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018–2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 –2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 –2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018–2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 –2030, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 –2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 –2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018–2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 –2030, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 –2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 –2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018–2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 –2030, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 –2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 –2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018–2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 –2030, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 –2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 –2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018–2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 –2030, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 –2030, (US$ Bn)
- `Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 –2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018–2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 –2030, (US$ Bn)
- North Africa
- Central Africa
- South Africa
- 9. Competitive Landscape
- Company Profiles
- Teva Pharmaceutical Industries Ltd.*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis AG
- GlaxoSmithKline Plc.
- AbbVie Inc.
- Merck & Co., Inc.
- Zydus Cadila
- Dr. Reddy’s Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Boehringer Ingelheim International GmbH
- Denali Therapeutics Inc.
- Biogen Inc.
- Prevail Therapeutics
- Eli Lilly and Company
- Voyager Therapeutics
- 10. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 39 market data tables and 23 figures on “Global Parkinsons Disease Therapeutics Market” – Global forecast to 2030
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook